Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
Phase 2
Recruiting
- Conditions
- Head and Neck Mucosal Melanomas
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 60
- Registration Number
- NCT03313206
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy
Phase 1
- Conditions
- Gynecologic Cancer
- Interventions
- Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)Radiation: External beam radiotherapy (EBRT)Radiation: Uterovaginal brachytherapyDrug: Chemotherapy (cisplatin)
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 18
- Registration Number
- NCT03308604
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône, France
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
Phase 2
- Conditions
- Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03244956
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 41
- Registration Number
- NCT03212651
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
Phase 1
Completed
- Conditions
- Head and Neck Squamous Cell CarcinomaLung CancerOesophageal Cancer
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 54
- Registration Number
- NCT03212469
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction
Phase 2
Terminated
- Conditions
- Very High Risk Neuroblastoma
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 34
- Registration Number
- NCT03165292
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇦🇹St. Anna Kinderspital GmbH, Vienna, Austria
🇮🇹Fondazione IRCCS Istituto nazionaleTumori, Milano, Italy
Optimized Angiomammography and Comparison With Standard Angiomammography
- Conditions
- Patients for Whom an Angiomammogram Examination is Requested Whether Its Indication
- Interventions
- Other: Angiommamography
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 100
- Registration Number
- NCT03155386
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot
Phase 2
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Detection and resection of sentinel lymph node
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 100
- Registration Number
- NCT03010553
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Prognostic and Predictive Biomarkers in Ovarian Cancers
Not Applicable
Recruiting
- Conditions
- Ovarian Cancer
- Interventions
- Procedure: Blood sample
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 350
- Registration Number
- NCT03010124
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 1
- Conditions
- Head and Neck Cancers
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 36
- Registration Number
- NCT02997332
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
© Copyright 2025. All Rights Reserved by MedPath